Multicenter Randomized Phase II Study of consecutive-day versus alternate-day treatment with S-1 as Second-line chemotherapy in advanced pancreatic cancer.
Phase of Trial: Phase II
Latest Information Update: 03 Nov 2017
Price : $35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms SCOTCH
- 31 Oct 2017 Status changed from recruiting to completed.
- 06 Jan 2015 Planned End Date changed from 1 Dec 2015 to 31 Dec 2016 as reported by the University Hospital Medical Information Network record.
- 22 Jan 2014 Status changed from not yet recruiting to recruiting as reported by the University Hospital Medical Information Network record.